Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

NCT03381430 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Qilu Pharmaceutical Co., Ltd.

Collaborators